NGM Biopharmaceuticals, Inc. – NASDAQ:NGM
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
NGM Biopharmaceuticals stock price monthly change
+1.32%
month
NGM Biopharmaceuticals stock price quarterly change
+29.41%
quarter
NGM Biopharmaceuticals stock price yearly change
-61.11%
year
NGM Biopharmaceuticals key metrics
Market Cap | 128.53M |
Enterprise value | 267.25M |
P/E | -2.07 |
EV/Sales | 4.82 |
EV/EBITDA | -1.72 |
Price/Sales | 6.06 |
Price/Book | 1.29 |
PEG ratio | 0.06 |
EPS | -1.69 |
Revenue | 4.41M |
EBITDA | -149.85M |
Income | -139.82M |
Revenue Q/Q | -99.09% |
Revenue Y/Y | -92.01% |
Profit margin | -293.98% |
Oper. margin | -300.45% |
Gross margin | 0% |
EBIT margin | -300.45% |
EBITDA margin | -3392.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNGM Biopharmaceuticals stock price history
NGM Biopharmaceuticals stock forecast
NGM Biopharmaceuticals financial statements
| Mar 2023 | 2.24M | -45.1M | -2007.12% |
|---|---|---|---|
| Jun 2023 | 1.42M | -38.26M | -2688.76% |
| Sep 2023 | 582K | -28.79M | -4947.94% |
| Dec 2023 | 165K | -27.67M | -16769.7% |
| 2025 | 100K | -94.25M | -94251.67% |
|---|---|---|---|
| 2026 | 8.91M | -89.79M | -1006.64% |
| 2027 | 29.6M | -64.34M | -217.39% |
| 2028 | 71.7M | -51.14M | -71.34% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 258837000 | 37.90M | 14.64% |
|---|---|---|---|
| Jun 2023 | 220544000 | 28.42M | 12.89% |
| Sep 2023 | 192150000 | 22.34M | 11.63% |
| Dec 2023 | 168868000 | 20.23M | 11.98% |
| Mar 2023 | -41.82M | 35.64M | 279K |
|---|---|---|---|
| Jun 2023 | -40.24M | 24.58M | 1.38M |
| Sep 2023 | -27.16M | 26.86M | 0 |
| Dec 2023 | -22.96M | 27.19M | 111K |
NGM Biopharmaceuticals alternative data
| Aug 2023 | 239 |
|---|---|
| Sep 2023 | 239 |
| Oct 2023 | 239 |
| Nov 2023 | 239 |
| Dec 2023 | 239 |
| Jan 2024 | 239 |
| Feb 2024 | 239 |
| Mar 2024 | 138 |
| Apr 2024 | 138 |
| May 2024 | 138 |
| Jun 2024 | 138 |
| Jul 2024 | 138 |
NGM Biopharmaceuticals other data
64.74%
+4.05%
of NGM is owned by hedge funds
119
-1
51.31M
+3.96M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 600 | 0 |
| Jan 2023 | 1093518 | 85082 |
| Nov 2023 | 94704 | 0 |
| Patent |
|---|
Application Filling date: 7 Feb 2022 Issue date: 11 Aug 2022 |
Application METHODS AND USES FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES Filling date: 27 Dec 2021 Issue date: 4 Aug 2022 |
Grant Filling date: 25 Aug 2017 Issue date: 28 Jun 2022 |
Grant Filling date: 7 Feb 2020 Issue date: 14 Jun 2022 |
Application Filling date: 19 Aug 2021 Issue date: 21 Apr 2022 |
Application Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Metabolic Disorders and Diseases Filling date: 23 Jun 2021 Issue date: 24 Mar 2022 |
Application Filling date: 5 Mar 2021 Issue date: 10 Mar 2022 |
Application Filling date: 22 Jun 2021 Issue date: 17 Feb 2022 |
Application Filling date: 21 Jun 2021 Issue date: 10 Feb 2022 |
Grant Utility: Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases Filling date: 11 Oct 2019 Issue date: 8 Feb 2022 |
-
When is NGM Biopharmaceuticals's next earnings date?
Unfortunately, NGM Biopharmaceuticals's (NGM) next earnings date is currently unknown.
-
Does NGM Biopharmaceuticals pay dividends?
No, NGM Biopharmaceuticals does not pay dividends.
-
How much money does NGM Biopharmaceuticals make?
NGM Biopharmaceuticals has a market capitalization of 128.53M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.02% to 4.42M US dollars.
-
What is NGM Biopharmaceuticals's stock symbol?
NGM Biopharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "NGM".
-
What is NGM Biopharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of NGM Biopharmaceuticals?
Shares of NGM Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NGM Biopharmaceuticals's key executives?
NGM Biopharmaceuticals's management team includes the following people:
- Dr. David J. Woodhouse Ph.D. Chief Executive Officer & Director(age: 55, pay: $725,750)
- Dr. Jin-Long Chen Ph.D. Founder, Chief Scientific Officer & Director(age: 62, pay: $690,750)
- Ms. Siobhan Nolan Mangini Chief Financial Officer and Principal Financial & Accounting Officer(age: 44, pay: $355,440)
-
Is NGM Biopharmaceuticals founder-led company?
Yes, NGM Biopharmaceuticals is a company led by its founder Dr. Jin-Long Chen Ph.D..
-
How many employees does NGM Biopharmaceuticals have?
As Jul 2024, NGM Biopharmaceuticals employs 138 workers.
-
When NGM Biopharmaceuticals went public?
NGM Biopharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 4 Apr 2019.
-
What is NGM Biopharmaceuticals's official website?
The official website for NGM Biopharmaceuticals is ngmbio.com.
-
Where are NGM Biopharmaceuticals's headquarters?
NGM Biopharmaceuticals is headquartered at 333 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact NGM Biopharmaceuticals?
NGM Biopharmaceuticals's mailing address is 333 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 02435555.
NGM Biopharmaceuticals company profile:
NGM Biopharmaceuticals, Inc.
ngmbio.comExchange:
NASDAQ
Full time employees:
138
Industry:
Biotechnology
Sector:
Healthcare
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
333 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001426332
ISIN: US62921N1054
CUSIP: 62921N105
